ArticleJACC. Case reports2025
Purulent Pericarditis: Treating a Medically-Complex Patient With Intrapericardial Antibiotics.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trends, disparities and projections of pericardial diseases related mortality in the United States: A 1999-2035 analysis using artificial deep neural network.American heart journal plus : cardiology research and practice · 2026Article
- Article
- Avoiding Diagnostic Anchoring: The Case for Systematic Evaluation of Pericardial Disease.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePurulent pericarditis is a rare, lethal complication of a bacterial pericardial infection. This case report outlines the protocol for instilling intrapericardial antibiotics for methicillin-sensitive Staphylococcus aureus (MSSA) pericarditis without fibrinolytics in a 51-year-old man. KEY STEPS: An appropriately sized percutaneous pericardial drain was placed. Then, a 3-day course of intrapericardial infusions of 50 mL vancomycin was begun. Drainage of all accessible fluid was performed before each infusion. The daily infusions each had an 8-hour dwell time. The prior drainage protocol continued after each infusion. POTENTIAL PITFALLS: Strict dosage and infusion length management are required to prevent direct toxicity. Potential complications include local inflammatory responses and constrictive pericarditis. TAKE-HOME MESSAGES: The use of simultaneous intravenous and intrapericardial antibiotics were used for treating MSSA purulent pericarditis without using intrapericardial fibrinolytics in an adult. This was noted to favorably improve the purulent output and relative safety without untoward complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.